References
- Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392(10153):1147–59. doi:https://doi.org/10.1016/s0140-6736(18)31550-2.
- Wong TY, Cheung CM, Larsen M, Sharma S, Simo R. Diabetic retinopathy. Nat Rev Dis Primers. 2016;2:16012. doi:https://doi.org/10.1038/nrdp.2016.12.
- Bashinsky AL. Retinopathy of prematurity. N C Med J. 2017;78(2):124–28. doi:https://doi.org/10.18043/ncm.78.2.124.
- Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27(7):787–94. doi:https://doi.org/10.1038/eye.2013.107.
- Cao Y, Cao R, Veitonmäki N. Kringle structures and antiangiogenesis. Curr Med Chem Anticancer Agents. 2002;2(6):667–81. doi:https://doi.org/10.2174/1568011023353705.
- Kim HK, Choi JS, Lee SW, Joo CK, Joe YA. A novel peptide derived from tissue-type plasminogen activator potently inhibits angiogenesis and corneal neovascularization. J Cell Biochem. 2017;118(5):1132–43. doi:https://doi.org/10.1002/jcb.25732.
- Gschwend TP, Krueger SR, Kozlov SV, Wolfer DP, Sonderegger P. Neurotrypsin, a novel multidomain serine protease expressed in the nervous system. Mol Cell Neurosci. 1997;9(3):207–19. doi:https://doi.org/10.1006/mcne.1997.0616.
- Yamamura Y, Yamashiro K, Tsuruoka N, Nakazato H, Tsujimura A, Yamaguchi N. Molecular cloning of a novel brain-specific serine protease with a kringle-like structure and three scavenger receptor cysteine-rich motifs. Biochem Biophys Res Commun. 1997;239(2):386–92. doi:https://doi.org/10.1006/bbrc.1997.7417.
- Wolfer DP, Lang R, Cinelli P, Madani R, Sonderegger P. Multiple roles of neurotrypsin in tissue morphogenesis and nervous system development suggested by the mRNA expression pattern. Mol Cell Neurosci. 2001;18(4):407–33. doi:https://doi.org/10.1006/mcne.2001.1029.
- Molinari F, Rio M, Meskenaite V, Encha-Razavi F, Auge J, Bacq D, Briault S, Vekemans M, Munnich A, Attie-Bitach T, et al. Truncating neurotrypsin mutation in autosomal recessive nonsyndromic mental retardation. Science. 2002;298(5599):1779–81. doi:https://doi.org/10.1126/science.1076521.
- Sulochana KN, Ge R. Developing antiangiogenic peptide drugs for angiogenesis-related diseases. Curr Pharm Des. 2007;13(20):2074–86. doi:https://doi.org/10.2174/138161207781039715.
- Van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. Jama. 2005;293(12):1509–13. doi:https://doi.org/10.1001/jama.293.12.1509.
- Smith LE, Wesolowski E, McLellan A, Kostyk SK, D’Amato R, Sullivan R, D’Amore PA. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101–11.
- Connor KM, Krah NM, Dennison RJ, Aderman CM, Chen J, Guerin KI, Sapieha P, Stahl A, Willett KL, Smith LE. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc. 2009;4(11):1565–73. doi:https://doi.org/10.1038/nprot.2009.187.
- Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248–64. doi:https://doi.org/10.1016/j.cell.2019.01.021.
- Tombran-Tink J. PEDF in angiogenic eye diseases. Curr Mol Med. 2010;10(3):267–78. doi:https://doi.org/10.2174/156652410791065336.
- Frischknecht R, Fejtova A, Viesti M, Stephan A, Sonderegger P. Activity-induced synaptic capture and exocytosis of the neuronal serine protease neurotrypsin. J Neurosci. 2008;28(7):1568–79. doi:https://doi.org/10.1523/jneurosci.3398-07.2008.
- Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342(6248):440–43. doi:https://doi.org/10.1038/342440a0.
- Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature. 1983;301(5897):214–21. doi:https://doi.org/10.1038/301214a0.
- Venugopal S, Kao C, Chandna R, Sulochana KN, Subramanian V, Chen M, Kini RM, Ge R. Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, suppresses tumor growth in mice via impeding both angiogenesis and vascular permeability. Angiogenesis. 2018;21(3):653–65. doi:https://doi.org/10.1007/s10456-018-9616-7.
- Cao Y, Chen A, An SS, Ji RW, Davidson D, Llinás M. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem. 1997;272(36):22924–28. doi:https://doi.org/10.1074/jbc.272.36.22924.
- Kim JS, Chang JH, Yu HK, Ahn JH, Yum JS, Lee SK, Jung KH, Park DH, Yoon Y, Byun SM, et al. Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). J Biol Chem. 2003;278(31):29000–08. doi:https://doi.org/10.1074/jbc.M301042200.
- Ahn JH, Yu HK, Lee HJ, Hong SW, Kim SJ, Kim JS. Suppression of colorectal cancer liver metastasis by apolipoprotein(a) kringle V in a nude mouse model through the induction of apoptosis in tumor-associated endothelial cells. PLoS One. 2014;9(4):e93794. doi:https://doi.org/10.1371/journal.pone.0093794.
- Lu Q, Zhang L, Shen X, Zhu Y, Zhang Q, Zhou Q, Gan R, Zhang H, Zhong Y, Xie B. A novel and effective human hepatocyte growth factor kringle 1 domain inhibits ocular neovascularization. Exp Eye Res. 2012;105:15–20. doi:https://doi.org/10.1016/j.exer.2012.10.004.
- Xu Y, Zhao H, Zheng Y, Gu Q, Ma J, Xu X. A novel antiangiogenic peptide derived from hepatocyte growth factor inhibits neovascularization in vitro and in vivo. Mol Vis. 2010;16:1982–95.
- Sun Q, Shen Y, Su L, Xu X. Inhibition of pathological retinal neovascularization by a small peptide derived from human tissue-type plasminogen kringle 2. Front Pharmacol. 2019;10:1639. doi:https://doi.org/10.3389/fphar.2019.01639.
- Su L, Xu X, Zhao H, Gu Q, Zou H. In vitro and in vivo antiangiogenic activity of a novel deca-peptide derived from human tissue-type plasminogen activator kringle 2. Biochem Biophys Res Commun. 2010;396(4):1012–17. doi:https://doi.org/10.1016/j.bbrc.2010.05.048.
- Tong JP, Yao YF. Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions. Clin Biochem. 2006;39(3):267–76. doi:https://doi.org/10.1016/j.clinbiochem.2005.11.013.
- Cai WB, Zhang Y, Cheng R, Wang Z, Fang SH, Xu ZM, Yang X, Yang ZH, Ma JX, Shao CK, et al. Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1α pathway. PLoS One. 2012;7(12):e53152. doi:https://doi.org/10.1371/journal.pone.0053152.
- Gao G, Li Y, Gee S, Dudley A, Fant J, Crosson C, Ma JX. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem. 2002;277(11):9492–97. doi:https://doi.org/10.1074/jbc.M108004200.
- Long Q, Cao X, Bian A, Li Y. C3a increases VEGF and decreases PEDF mRNA levels in human retinal pigment epithelial cells. Biomed Res Int. 2016;2016:6958752. doi:https://doi.org/10.1155/2016/6958752.
- Williamson MP. The structure and function of proline-rich regions in proteins. Biochem J. 1994;297(Pt 2):249–60. doi:https://doi.org/10.1042/bj2970249.
- Antosova Z, Mackova M, Kral V, Macek T. Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol. 2009;27(11):628–35. doi:https://doi.org/10.1016/j.tibtech.2009.07.009.
- Di L. Strategic approaches to optimizing peptide ADME properties. Aaps J. 2015;17(1):134–43. doi:https://doi.org/10.1208/s12248-014-9687-3.
- Campochiaro PA, Marcus DM, Awh CC, Regillo C, Adamis AP, Bantseev V, Chiang Y, Ehrlich JS, Erickson S, Hanley WD, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial. Ophthalmology. 2019;126(8):1141–54. doi:https://doi.org/10.1016/j.ophtha.2019.03.036.